替格瑞洛用于经皮冠状动脉介入治疗术后患者抗血小板治疗短期内的有效性和安全性研究

目的：观察替格瑞洛用于经皮冠状动脉介入治疗（PCI）患者抗血小板治疗的有效性和安全性。方法选择50例冠心病PCI术后应用氯吡格雷抗血小板，因血小板聚集率不达标且CYP2C19基因异常而改用替格瑞洛的患者。所有入选患者应用阿司匹林首次负荷剂量300 mg，维持剂量100 mg，每日一次；替格瑞洛维持剂量90 mg，每日二次，持续1年。研究主要终点为随访1个月的主要不良心血管事件（包括死亡、支架内血栓形成、支架内再狭窄、非致死性心肌梗死、靶血管血运重建）和脑卒中的发生率；次要终点为一般不良事件（包括轻微出血、过敏、呼吸困难）的发生率及血小板计数的变化情况。结果患者应用替格瑞洛后随访1个月未出现主要不良心血管事件和脑卒中；一般不良事件的发生率较低，2例（4%）出现呼吸困难，2例（4%）发生轻微出血，其中1例鼻出血，1例皮下淤血。应用替格瑞洛后血小板聚集率明显低于氯吡格雷，血小板计数未明显下降。结论替格瑞洛用于存在氯吡格雷抵抗的PCI患者抗血小板治疗，短期内安全有效。

Short term clinical efficacy and safety of ticagrelor in patients received percutaneous coronary intervention

Objective To observe the efifcacy and safety of ticagrelor in patients received percutaneous coronary intervention （PCI）. Methods 50 patients with non-responding platelet aggregation rate and CYPC219 gene after clopidogrel treatment were given ticagrelor and enrolled in the study. All enrolled patients received aspirin loading dosage 300 mg, followed by maintenance dosage 100 mg, once daily and ticagrelor maintenance dosage 90 mg twice daily, for 1 year. The primary endpoint for the study were the incidence of major cardiovascular events （including death, stent thrombosis, stent restenosis, nonfatal myocardial infarction, target vessel revascularization） and stroke after followed up for a month. The secondary endpoint were the incidence of general events （including minor bleeding, allergies, breathing dififculties） and platelet count changes. Results No occur major cardiovascular and stroke events record after 1 month of ticagrelor treatment. The general events rates included 2 cases of dyspnen, 1 case of epitaxis and 1 case of subcutaneous bleeding. The platelet aggregation with ticagrelor was signiifcantly lower than clopidogrel without signiifcant decrease in platelets count. Conclusions Using ticagrelor for antiplatelet in patients with coronary artery stenting in clopidogrel resistance cases is safe and effective.